FDA Rule and Companion Guidance Make Early Stage Clinical Drug Development Safe and Efficient

July 18, 2008--The U.S. Food and Drug Administration today issued a final regulation that makes early phase 1 clinical drug development safe and efficient by enabling a phased approach to complying with current good manufacturing practice (CGMP) statutes and FDA investigational requirements.

The details can be read here.